Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $3,489,673.32 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 315,522 shares of Roivant Sciences stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $11.06, for a total transaction of $3,489,673.32. Following the transaction, the chief operating officer now directly owns 959,457 shares in the company, valued at $10,611,594.42. The trade was a 24.75 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Eric Venker also recently made the following trade(s):

• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96.
• On Thursday, February 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.65, for a total transaction of $1,065,000.00.
• On Thursday, February 13th, Eric Venker sold 218,041 shares of Roivant Sciences stock. The stock was sold at an average price of $10.42, for a total value of $2,271,987.22.
• On Tuesday, January 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00.
• On Monday, December 30th, Eric Venker sold 177,704 shares of Roivant Sciences stock. The shares were sold at an average price of $11.54, for a total value of $2,050,704.16.
• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.

Roivant Sciences Stock Down 2.2 %

Shares of ROIV stock opened at $10.44 on Thursday. The firm has a market cap of $7.45 billion, a PE ratio of -69.60 and a beta of 1.26. Roivant Sciences Ltd. has a 12 month low of $9.96 and a 12 month high of $13.06. The company’s fifty day simple moving average is $10.77 and its 200-day simple moving average is $11.43.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities analysts predict that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on ROIV shares. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $17.10.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ROIV. Treasurer of the State of North Carolina boosted its holdings in shares of Roivant Sciences by 0.6% in the 4th quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company’s stock valued at $2,213,000 after buying an additional 1,170 shares during the last quarter. GAMMA Investing LLC raised its position in Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock worth $42,000 after acquiring an additional 1,288 shares in the last quarter. WINTON GROUP Ltd lifted its stake in Roivant Sciences by 1.5% in the fourth quarter. WINTON GROUP Ltd now owns 92,526 shares of the company’s stock valued at $1,095,000 after acquiring an additional 1,332 shares during the last quarter. Covestor Ltd grew its position in shares of Roivant Sciences by 7.5% in the 4th quarter. Covestor Ltd now owns 20,634 shares of the company’s stock valued at $245,000 after acquiring an additional 1,444 shares during the period. Finally, PNC Financial Services Group Inc. increased its stake in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock worth $84,000 after purchasing an additional 1,507 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.